SCHEMBL5709109

SCHEMBL5709109

O=C(NCCS(=O)(=O)O)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.60
NAAA Q02083 1/20 0.57
HDAC3 O15379 1/20 0.57
HDAC4 P56524 1/20 0.57
HDAC1 Q13547 1/20 0.57
HDAC7 Q8WUI4 1/20 0.57
HDAC2 Q92769 1/20 0.57
HDAC10 Q969S8 1/20 0.57
HDAC11 Q96DB2 1/20 0.57
HDAC8 Q9BY41 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
HDAC9 Q9UKV0 1/20 0.57
HDAC5 Q9UQL6 1/20 0.57
GAA P10253 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.56
LMNA P02545 1/20 0.56
POLB P06746 1/20 0.56
EPHX2 P34913 1/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2168052 0.89 HDAC1 (0.63) L3MBTL1NAAAHDAC3HDAC4HDAC1
SCHEMBL6570646 0.88 HDAC1 (0.61) L3MBTL1NAAAHDAC3HDAC4HDAC1
SCHEMBL2169842 0.88 HDAC1 (0.61) L3MBTL1NAAAHDAC3HDAC4HDAC1
SCHEMBL6572367 0.88 HDAC1 (0.61) L3MBTL1NAAAHDAC3HDAC4HDAC1
SCHEMBL28011647 0.87 NAAA (0.52) L3MBTL1NAAAHDAC3HDAC4HDAC1
SCHEMBL18877141 0.86 TRPA1 (0.49) L3MBTL1NAAAHDAC3HDAC4HDAC1
SCHEMBL4564262 0.84 L3MBTL1 (0.59) L3MBTL1NAAAGAASMN1; SMN2LMNA
SCHEMBL668703 0.84 L3MBTL1 (0.59) L3MBTL1GAASMN1; SMN2LMNAPOLB
SCHEMBL9188848 0.82 HDAC8 (0.58) HDAC8SMN1; SMN2LMNANPC1RAB9A
SCHEMBL24052293 0.82 CA2 (0.50) L3MBTL1HDAC2HDAC8HDAC6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108686634-B Solid phase for mixed mode chromatographic purification of proteins 生物辐射实验室股份有限公司 2021-03-16 CN claimed
US-20200391196-A1 SOLID PHASE FOR MIXED-MODE CHROMATOGRAPHIC PURIFICATION OF PROTEINS BIO RAD LABORATORIES (US) 2020-12-17 US claimed
CN-108686634-A The solid phase of hybrid chromatogram purification for protein 生物辐射实验室股份有限公司 2018-10-23 CN claimed
EP-2768843-A1 SOLID PHASE FOR MIXED-MODE CHROMATOGRAPHIC PURIFICATION OF PROTEINS Bio-Rad Laboratories, Inc. (US) 2014-08-27 EP claimed
CN-103998456-A Solid phase for mixed mode chromatographic purification of proteins BIO RAD LABORATORIES 2014-08-20 CN claimed
US-20130102761-A1 SOLID PHASE FOR MIXED-MODE CHROMATOGRAPHIC PURIFICATION OF PROTEINS BIO-RAD LABORATORIES, INC. (US) 2013-04-25 US claimed
WO-2013059690-A1 SOLID PHASE FOR MIXED-MODE CHROMATOGRAPHIC PURIFICATION OF PROTEINS BIO-RAD LABORATORIES, INC. (US) 2013-04-25 WO claimed
EP-0867558-B1 Cloth for textile printing, textile printing process using the cloth and print obtained thereby CANON KK (JP) 2006-10-18 EP claimed
US-6200667-B1 INK-JET PRINTING A CLOTH OF COTTON OR SILK FIBER USING A REACTIVE DYE AND A COMPOUND(S) OF PYRIDINE-3-CARBOXYLIC ACID, BISHYDROXYETHYL-TAURINE, HIPPURIC ACID, BENZOYLTAURINE; NONBLEEDING COLOR INTENSITY; CLARITY CANON KABUSHIKI KAISHA (JP) 2001-03-13 US claimed
EP-0867558-A2 Cloth for textile printing, textile printing process using the cloth and print obtained thereby CANON KABUSHIKI KAISHA (JP) 1998-09-30 EP claimed
US-11590486-B2 Solid phase for mixed-mode chromatographic purification of proteins BIO-RAD LABORATORIES, INC. (US) 2023-02-28 US disclosed
CN-108686634-B Solid phase for mixed mode chromatographic purification of proteins 生物辐射实验室股份有限公司 2021-03-16 CN disclosed
US-20200391196-A1 SOLID PHASE FOR MIXED-MODE CHROMATOGRAPHIC PURIFICATION OF PROTEINS BIO RAD LABORATORIES (US) 2020-12-17 US disclosed
US-10792654-B2 Solid phase for mixed-mode chromatographic purification of proteins BIO-RAD LABORATORIES, INC. (US) 2020-10-06 US disclosed
CN-108686634-A The solid phase of hybrid chromatogram purification for protein 生物辐射实验室股份有限公司 2018-10-23 CN disclosed
US-20070111125-A1 CHARGE CONTROLLING AGENT AND TONER CANON KABUSHIKI KAISHA (JP) 2007-05-17 US disclosed
US-20070111125-A1 CHARGE CONTROLLING AGENT AND TONER CANON KABUSHIKI KAISHA (JP) 2007-05-17 US disclosed
EP-0867558-B1 Cloth for textile printing, textile printing process using the cloth and print obtained thereby CANON KK (JP) 2006-10-18 EP disclosed
US-6200667-B1 INK-JET PRINTING A CLOTH OF COTTON OR SILK FIBER USING A REACTIVE DYE AND A COMPOUND(S) OF PYRIDINE-3-CARBOXYLIC ACID, BISHYDROXYETHYL-TAURINE, HIPPURIC ACID, BENZOYLTAURINE; NONBLEEDING COLOR INTENSITY; CLARITY CANON KABUSHIKI KAISHA (JP) 2001-03-13 US disclosed
EP-0867558-A2 Cloth for textile printing, textile printing process using the cloth and print obtained thereby CANON KABUSHIKI KAISHA (JP) 1998-09-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10792654-B2 Solid phase for mixed-mode chromatographic purification of proteins AFG3L2, MRPL21, SSBP1 L3MBTL1 2642/4885NAAA 1310/4885HDAC3 2582/4885
US-20200391196-A1 SOLID PHASE FOR MIXED-MODE CHROMATOGRAPHIC PURIFICATION OF PROTEINS MRPL21, SCAMP2, AFG3L2 L3MBTL1 2496/4885NAAA 3171/4885HDAC3 3366/4885
US-20130102761-A1 SOLID PHASE FOR MIXED-MODE CHROMATOGRAPHIC PURIFICATION OF PROTEINS MRPL21, SCAMP2, AFG3L2 L3MBTL1 2496/4885NAAA 3171/4885HDAC3 3366/4885
US-11590486-B2 Solid phase for mixed-mode chromatographic purification of proteins SAMM50, MAX, RAB5IF L3MBTL1 3473/4885NAAA 2293/4885HDAC3 4566/4885
US-20070111125-A1 CHARGE CONTROLLING AGENT AND TONER CA2, ACTR2, CA12 L3MBTL1 4774/4885NAAA 91/4885HDAC3 1039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.